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Background & Aim: Prostate cancer is one of the most common cancers in males and the second 
leading cause of cancer-related deaths in Palestine. Although, many studies were conducted in de- 
veloped countries to evaluate quality of life (QOL) in survivors of prostate cancer, the researchers 
could not find any study that was conducted in a developing country including Palestine. Therefore, 
the purpose of this study was to evaluate the QOL of prostate cancer survivors residing in Gaza 
Strip, Palestine, as an example of a developing country, and compare it with the literature. 
Methods & Materials: A total of a 121 men who were diagnosed with prostate cancer and live in 
Gaza Strip participated in this cross-sectional study. The University of California at Los Angeles 
Prostate-Specific Index including the RAND 36-Item Health Survey v2 was used to assess QOL of 
participants. 
Results: Age of participants’ ranged between 52 and 89 years with a mean of 71.80 (SD 7.66). The 
greatest majority of participants (n = 94, 77.67%) were diagnosed with prostate cancer after the age 
of 60. The mean scores for the entire general QOL items was 47.93 (SD = 22.46) and the mean for 
all Prostate Cancer Index - University of California items was 44.20 (SD = 16.16). 
Conclusion: Prostate cancer survivors living in Gaza Strip, Palestine have lower level of QOL than 
their counterparts who live in developed courtiers. These differences could be related to early 
screening and advanced technology used to treat prostate cancer in developed countries. Health care 
providers and health care policy makers need to improve provided health care services and introduce 
screening method to diagnose prostate cancer early. Further studies are recommended to compare 
QOL of prostate cancer survivors living in developing countries and developed countries. 
 
 
 
Introduction 
 
Because of advanced medical technology that 
we have today, people can live longer than ever 
before. The chances of developing chronic dis- 
eases, such as cancer, have also increased. It was 
estimated that over 12 million new cases of can- 
cer was diagnosed worldwide in 2007. Approx- 
imately, half of these were in economically de- 
veloped countries. About 6.7 million of  these 
cases  resulted  in  death.  Approximately,  two- 
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thirds of those were patients residing in develop- 
ing countries (1). 
Worldwide, one of the most commonly diag- 
nosed cancers in men is prostate cancer. It is the 
second most common type of cancer diagnosed 
among men and it is the sixth leading cause of 
cancer-related deaths in men worldwide. In de- 
veloped countries, prostate cancer is ranked as 
the most commonly diagnosed cancer in men; 
being the second cause of cancer-related deaths. 
In developing countries, it is ranked as the sixth 
most commonly diagnosed cancer in men; being 
the sixth most common cause of death among 
men (1). 
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In 2005, prostate cancer was the second most 
commonly diagnosed type of cancer among Pal- 
estinian males (Figure 1). It accounted for 11.3% 
of total new cancer cases among Palestinian 
males. In the same year, prostate cancer was re- 
ported as the second leading cause of cancer- 
related deaths (9.5%) among Palestinian males 
(2). The majority of new prostate cancer cases 
diagnosed between 1995 and 2000 (78.3%) were 
diagnosed after the age of 60. The peak inci- 
dence of occurrence (25.5%) was between the 
ages of 65 and 69 (3). 
The variation of the number of deaths related 
to cancer between developed and developing (or 
underdeveloped) countries can be related to 
screening strategies and advanced medical tech- 
nology in the developed countries. Digital rectal 
examination (DRE) and prostate-specific antigen 
(PSA) screening are routinely used for early de- 
tection of prostate cancer in many developed 
countries. In addition, there are several other 
advanced diagnostic technologies available, 
which may help in the early diagnosis of pros- 
tate cancer. Examples of these diagnostic tech- 
niques include transrectal ultrasound and ad- 
vanced techniques for prostate biopsy (4). Lack 
of advanced diagnostic techniques in underde- 
veloped countries can lead to many cases going 
undiagnosed. According to the American Cancer 
Society (5), some autopsy studies revealed that 
many men who died from other diseases were 
found to also have prostate cancer. This cancer 
though had never caused a  problem for them 
while they were alive. 
In spite of prostate cancer being one of the 
most common types of cancers among males, 
survival rates have improved in recent years. 
Between 1996 and 2002, the 5-year relative sur- 
vival rate (the chance to live 5 years after the 
diagnosis with prostate cancer) for men diag- 
nosed in the United States, improved to 99.9% 
for all stages of prostate cancer and 100% if it 
remained localized (6, 7). 
Prostate cancer can be treated by different mo- 
dalities such as prostatectomy, radiation therapy, 
or watchful waiting. Depending on the case, 
chemotherapy or hormonal therapy can be added 
to the treatment regimen (4, 6). The use of each 
treatment option has its own side effects and com- 
plications. Each of them can have several long- 
lasting complications that could negatively affect 
the QOL for prostate cancer survivors (8). Howev- 
er, due to  advanced medical technology in  the 
treatment and early diagnosis of prostate cancer, 
larger numbers of patients are surviving. They are 
living with less pain, physical limitations, and 
treatment-related complications. They may remain 
free from cancer for the rest of their lives. 
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Figure 1. Most common types of cancers among males in Palestine in 2005 
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On the other hand, men diagnosed with pros- 
tate cancer and residing in a developing country 
are lacking the advantage of having such ad- 
vanced medical technology (1). Therefore, pros- 
tate cancer may not be diagnosed in the early 
stages. It may be diagnosed at a later more ad- 
vanced stage. Later diagnoses require more ag- 
gressive and extensive treatments, as well as, the 
addition of other treatment options, such as 
chemotherapy and/or hormonal therapy. Late di- 
agnoses and the use of hormonal and/or chemo- 
therapy increase the number of complications. 
This can negatively impact the patients’ QOL. 
Therefore, it is expected that men who are diag- 
nosed with prostate cancer and reside in develop- 
ing countries, including the Gaza Strip, will have 
lower levels of QOL, as compared to those who 
live in more developed countries. Despite the rel- 
atively  large  number of  studies examining the 
QOL of prostate cancer survivors, little is known 
about their QOL specific to developing countries. 
None is  known about the  QOL of  Palestinian 
prostate cancer survivors. Therefore, the purpose 
of this study was to evaluate the QOL of prostate 
cancer survivors residing in a developing (under- 
developed) country (Gaza Strip, Palestine). For 
the purpose of this study, QOL is defined as “a 
person’s sense of well-being that stems from sat- 
isfaction or dissatisfaction with the areas of life 
that are important to him/her” (9). 
 
Methods 
 
The design for this study was a cross- 
sectional and descriptive design. 
All patients diagnosed with prostate cancer, 
regardless of its stage or method of treatment, 
and live in Gaza Strip were targeted to partici- 
pate in this study. Potential candidates were ap- 
proached at one of the two available medical 
centers where they receive their treatment. After 
explaining the purpose of the study, participants 
were invited to sign a consent paper to partici- 
pate in the study. Due to the high illiteracy rate 
among this group of patients, participants were 
interviewed privately to fill the questionnaire 
items between August and November, 2009. 
The researchers used the University of Cali- 
fornia Prostate Cancer Index (UCLA-PCI), in- 
cluding the RAND 36-Item Health Survey v2 
(SF-36 v2) to assess health-related QOL (HR- 
QOL) in this study. The UCLA Index includes 
items for assessing the general HR-QOL. It also 
includes pertinent items specific for  assessing 
HR-QOL related to prostate cancer. The instru- 
ment includes three parts: (a) the RAND 36-Item 
Health Survey v2 (SF-36 v2), (b) the UCLA- 
PCI, and (c) the socio-demographic data (10). 
The SF-36 v2 consists of 36 items that assess 
eight health domains considered to represent the 
most frequently used concepts in relevant health 
surveys. This also includes those affected by 
several diseases and treatment (11). These do- 
mains include the following areas: physical 
functioning, role physical (role limitation due to 
physical health problems), bodily pain, general 
health, vitality (energy/fatigue), social function- 
ing, role emotional (role limitation due to emo- 
tional problems), and mental health (psychologi- 
cal  distress  and  psychological  well-being).  It 
also  includes  one  item  in  which  the  patient 
makes a statement about the evaluation of their 
health status (11). The scores recorded for each 
scale range from 0 to 100, with the higher scores 
referring to a better level of QOL. 
The UCLA-PCI contains 20 items that cover 
six sub-domains that are specific to prostate can- 
cer. These domains are urinary function and 
bother, bowel function and bother, and sexual 
function and bother (12). The UCLA-PCI and 
the SF-36 have been proven to be both valid and 
reliable (12-17). 
These  instruments were  translated into  the 
Arabic language by the researchers. Some ex- 
pressions were modified due to cultural differ- 
ences. Words used to measure distance such as 
miles, yards, blocks were replaced by words us- 
ing the metric system. Words like playing golf 
and bowling were translated to activities such as 
gardening and sport activities to refer to moder- 
ate  activities.  After  translating  the  instrument 
into the Arabic language, it was then back trans- 
lated into English by a third bilingual nurse. 
Back-translation is a standard procedure for 
translating a research questionnaire from English 
to other languages (18). 
Prior to using the instrument in this study, the 
content validity and reliability of the translated 
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instrument was examined. The instrument was 
reviewed by five expert nurses. They were asked 
to rank each item on a  four point scale with 
1  =  not  relevant,  2  =  somewhat  relevant, 
3 = quite relevant, and 4 = highly relevant. Their 
results of this study and the results reported in 
the literature were statistically significant or not, 
t-test was used. The following formula was used 
to calculate the t value (20): 
ݐ  =  
௫భ ି௫మ 
responses were dichotomized into two variables: 
relevant and not relevant. Then the Item Content 
Validity Index (I-CVI) of these ratings was cal- 
culated by figuring out the proportion of items 
that were rated as relevant by all five experts. 
ඨ ೞభ 
೙భ
 
Results 
ା 
ೞమ 
೙మ
 
The result showed that the I-CVI of each item 
was 100% and were considered relevant accord- 
ing to Polit and Beck (19). The Arabic version 
of the instrument was found to be reliable with a 
Cronbach’s alpha of 0.83. 
After translating the instrument, 10 patients 
were randomly selected from the sample frame 
and were interviewed by the researchers to eval- 
uate the clarity of the Arabic version of the ques- 
tionnaire and to determine whether it was friend- 
ly and easy to understand. The pilot study also 
investigated the following: (1) how long it takes 
to complete the questionnaire; (2) whether par- 
ticipants felt they had enough opportunity to 
share their views; (3) suggestions for changes; 
(4) other comments. 
Participants in the pilot study reported that the 
instrument was friendly to use and that the items 
were easily understood. Only one suggestion was 
addressed about the wording of questions. That 
was about another Arabic expression to the Eng- 
lish Expression “sexual intercourse” to help less 
educated people to more understand what meant 
by this item. Other than that, participants in the 
pilot study did not suggest any changes in the 
wording of the instrument. The suggestion was 
taken into consideration and was added into 
bracket. Finally, the average time to answer the 
questionnaire was between 25 and 40 min. 
The Statistical Package for Social Science 
(SPSS) was used to analyze and compute the 
data. Before analyzing the data, results reported 
by participants (Likert’s scale) were converted 
(according to  a  formula that  accompanies the 
instrument into scores that ranged between 0 and 
100). Basic descriptive statistical procedures 
including mean, range, standard deviation, and 
percentage were used to analyze the results. In 
order to determine if the differences between the 
The target population for this study was all 
patients diagnosed with prostate cancer, regard- 
less of its stage or method of treatment, and 
living in the Gaza Strip. A total of 121 out of 
124 of all recruited patients agreed to partici- 
pate in the study with a final response rate of 
97.98%. 
Table 1  includes a  summary of  the socio- 
demographic statistics of the participants. Age of 
participants’ ranged between 52 and 89 years 
with a mean of 71.80 (SD 7.66). The majority of 
participants (n = 79, 65.29%) were ≥70 years 
old.  The greatest  majority of participants 
(n = 94, 77.67%) were diagnosed with prostate 
cancer  after  the  age  of  60.  About  one-third 
of participants did not  attend school 
(n = 41, 33.88%) and a small number of them 
(n = 12, 9.92%) finished their higher education. 
The majority of participants (n = 92, 76.03%) 
were married and living with their wives. The 
rest were either divorced or widowed. A rela- 
tively small number of participants (14, 11.57%) 
were diagnosed with another type of cancer in 
addition to cancer of the prostate. 
Participants had previously received several 
types and combinations of therapy for their can- 
cer. The most common type of mono-therapy 
was hormonal therapy (n = 56, 46.28%). Fifteen 
participants  (12.4%)  reported  that  they  were 
treated  by  prostatectomy alone.  Other  partici- 
pants reported receiving a combination of two or 
more types of treatment modalities. 
The UCLA-PCI was used to assess QOL of 
participants. UCLA-PCI divides the QOL into 
two categories. The first category covers nine 
sub-domains (Table 2). It measures general QOL 
(SF-36) issues. The second category (Table 3) 
includes six sub-domains and measures Prostate- 
Specific QOL (PCI-QOL). After converting the 
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Mean by years 71.80 (bowel  bother).  The  mean  f 
Standard deviation 7.66 items was 44.20 (SD = 16.16). 
 
< 60 5 4.13 
60–64 17 14.05 
65–69 20 16.53 
70–74 34 28.10 
> 75 45 37.19 
 
Divorced or widowed 29 23.97 
Types of treatment received   
Prostatectomy 15 12.40 
Hormonal therapy 56 46.28 
Prostatectomy and hormonal thera py 21 17.36 
Hormonal and chemotherapy 11 9.09 
Prostatectomy and chemotherap y 6 4.96 
Hormonal   therapy   and   radia tion 5 4.13 
 
 
 
Table 1. Socio-demographic characteristics of pros- 
tate cancer survivors residing in Gaza Strip   
  Characteristics  N  %   
Age 
QOL items was 47.93 (SD = 22.46). On the oth- 
er hand, scores of PCI-QOL (Table 3) ranged 
between  10.02  (sexual  function)  and  89.74 
or  all  PCI-QOL 
 
Age by category (years) 
 
 
 
 
 
Level of education 
No school 41 33.88 
Some education below primary school 23 19.01 
Finished primary school 11 9.09 
Finished secondary school 11 9.09 
Finished high school 23 19.01 
Higher education 12 9.92 
Relationship status 
Live with wife 92 76.03 
 
 
 
 
 
 
 
 
therapy 
  Other combination therapies  7  5.78   
 
participants’ responses into scores, the mean of 
each sub-domain was calculated. The mean for 
all items of the SF-36 and the PCI were also cal- 
culated.  Scores  of  the  general  QOL  (SF-36 
QOL)  items  ranged  (Table  2)  between  33.97 
(role  limitation:  emotional) and  68.23  (bodily 
pain). The mean scores for the entire general 
 
Discussion 
 
Many studies were conducted to evaluate the 
QOL of males diagnosed with prostate cancer. 
Several instruments were used to assess QOL of 
prostate cancer survivors. In order to compare 
the results of this study with the literature, addi- 
tional studies that used the UCLA-PCI instru- 
ment  were  reviewed  and  the  reported  scores 
were summarized in Table 4. 
In comparing the scores of SF-36 QOL re- 
ported in the literature, with the scores reported 
by participants of this study (Table 4); it will be 
noticed that the scores reported by participants 
of this study were lesser than those reported in 
the literature with one exception. Participants of 
Ishihara’s et al. (23) study reported a slightly 
lower score (56) for the general health sub- 
domain compared to the score reported by par- 
ticipants of this study (59.19). 
Similarly, it can be noted that all of the scores 
reported in this study relate to urinary function 
and urinary bother of the UCLA-PCI sub- 
domains. These are less than those reported in the 
literature. Most of the results related to sexual 
function and sexual bother are less than those 
reported in the literature with a few exceptions. 
There  is  one  exception in  the  sexual  function 
 
Table 2. Scores of general QOL (SF-36) and their sub-domains 
 
 Number of items Mean SD 
SF-36    
Physical function 10 45.09 30.13 
Role limitation – physical 4 35.26 34.95 
Role limitation – emotional 3 33.97 34.27 
Vitality 4 46.84 25.37 
Mental health 5 55.56 20.03 
Social functioning 2 59.66 31.93 
Bodily pain 2 68.23 31.14 
General health 6 59.19 34.83 
Health transition 1 50.34 27.18 
General QOL (SF-36)  47.93 22.46 
QOL: Quality of life 
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 Number of items Mean SD 
PCI    
Urinary function 5 57.08 32.12 
Urinary bother 1 39.74 37.31 
Bowel function 4 84.96 16.63 
Bowel bother 1 89.74 20.54 
Sexual function 8 10.02 28.42 
Sexual bother 1 49.15 20.54 
 
 
 
sub-domain of Inoue, et al. study (32) and five 
exceptions in the sexual bother sub-domains in 
the following studies: Litwin et al. (14), Jaya- 
devappa et al. (24), Arredondo et al. (25), 
Karakiewicz, et al. (29), and Berge, et al. (33) 
The scores related to bowel function and bowel 
bother fall within the range of the scores reported 
in the literature. These similar results may relate 
to the small number of participants of this study 
who were treated with radiation therapy. As radi- 
ation therapy causes most of the complications 
related to bowel function and bowel bother. 
In spite of the noticed variances among re- 
ported scores and literature; it cannot be inferred 
that these variances are real and statistically sig- 
nificant. Differences among scores may be simp- 
ly due to chance or sample fluctuation. In order 
to examine that the differences were not due to 
chance or sampling errors, a t-test was calculat- 
ed for all studies using the formula mention in 
the methodology. 
Results of calculated t-tests are presented in 
Table 5. As all the studies had more than 120 
participants with the exception of two studies 
[Jayadevappa et al. (24), n = 115 and Berge, et 
al. (33), n = 61], the critical value of 1.98 at an 
alpha of 0.05 was used to infer the significance 
of the differences between scores reported in this 
study and those reported in the reviewed studies. 
While reviewing Table 5, it is apparent that 
the SF-36 QOL scores of this study were lesser 
than  those reported by  other  studies. Further- 
more, the t-test values exceeded the critical val- 
ue of 1.98 which reflects the differences as being 
statistically significant. When examining the 
results  of  the  t-test  of  the  PCI  sub-domains, 
those indicating urinary function, urinary bother, 
sexual function and sexual bother, also exceeded 
the critical value of 1.98 denoting the statistical 
significance of these differences. This compari- 
son reveals that prostate cancer survivors resid- 
ing in the Gaza Strip were not experiencing the 
same level of QOL as their counterparts in more 
developed countries. This was shown by lower 
scores of SF-36 and UCLA-PCI sub-domains, 
with  the  exception, of  those related to  bowel 
function and bowel bother. 
The low scores reported in this study compared 
with those reported in the literature could be relat- 
ed to the fact that this study was conducted in a 
developing country. Those reviewed in the litera- 
ture were conducted in more developed countries 
including, the USA, Canada, Germany, Italy, The 
Netherlands, Australia, and Japan. Developed 
countries have more facilities for early diagnosis 
than  the  developing  countries.  They  also  have 
more advanced medical technology and more ex- 
perienced physicians. Advanced medical technol- 
ogy and the use of advanced screening techniques 
such as, DRE and PSA, and other tests, can help to 
diagnose asymptomatic patients. They also help to 
diagnose prostate cancer at the earlier stages of its 
occurrence (35-38). In fact, the majority of newly 
diagnosed cases of prostate cancer (about 57%) are 
discovered while the tumor is still localized (39). 
This of course improves the prognosis, survival 
rate, and QOL of these patients, especially with the 
advance of the better treatment modalities now 
available in these countries. 
Therefore, it can be expected that patients liv- 
ing in developed countries will have higher scores 
of QOL than those living in the Gaza Strip, Pales- 
tine as an example of still developing countries. 
In order to further examine this hypothesis, the 
researchers recommend further studies to be con- 
ducted in developing countries to assess the QOL 
of prostate cancer survivors. The researchers also 
recommend the need to conduct a comparative 
study that includes participants from both a de- 
veloped and a developing country. This would be 
a study that compares the QOL of prostate cancer 
survivors in these countries. 
 
Table 3. Scores of UCLA-PCI and their sub-domains 
 
 
 
 
 
 
 
   Total score of PCI  44.20  16.16   
UCLA-PCI: University of California Prostate Cancer Index 
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Table 4. A comparison between the result of this study and the results of other studies that used the UCLA-PCI 
 
 This 
study 
Litwin, 
et al. (14) 
Korfage, 
et al. (21) 
Gacci, 
et al. (22) 
Ishihara, 
et al. (23) 
Jayadevappa 
et al. (24) 
Arredondo 
et al. (25) 
Namiki, 
et al. (26) 
This 
study 
Shikanov 
et al. (27) 
Wakatsuki 
et al. (28) 
Karakiewicz, 
et al. (29) 
Krahn, 
et al. (30) 
Wootten, 
et al. (31) 
Inoue, 
et al. (32) 
Berge, 
et al. (33) 
Smith, 
et al. (34) 
Country Gaza USA Netherlands Italy Japan USA USA Japan Gaza USA Japan Canada Canada Australia Japan Norway USA 
Physical function 45.09 72.5  86.87 85.7 69.8 80.2  45.09   80.95     87 
Role limitation – physical 35.26 61.3  72.73 71.4 69.8 67.6  35.26   70.67     78 
Role limitation – emotional 33.97 71.2  55.30 70.1 95.2 80.2  33.97   77.52     86 
Vitality 46.84 62.2  81.94 62 74.1 62.3  46.84   64.75     67 
Mental health 55.56 76.7  72.63 64.2 85.4 77.2  55.56        81 
Social functioning 59.66 80.0  80.18 79.5 92.9 81.9  59.66   82.13     90 
Bodily pain 68.23 73.3  86.79 74.1 86.1 79.5  68.23   81.56     82 
General health 59.19 67.0  66.36 56 73.5 71.1  59.19   71.31     76 
Health transition 50.34   80.05   50.4  50.34         
Urinary function 57.08 83.8 85.0 75.18 84.2 77.1 69.9 81 57.08 72.0 82.5 70.86 90 79.44 71.8 79.7 75 
Urinary bother 39.74 79.4 80.5 75.44 72.9 85.7 73.4 81 39.74 79.0 79.2 74.30  86.89 80.6 83.8 38 
Bowel function 84.96 84.4 86.6 89.80 86 92.2 84.1 89 84.96  90.3  88  86.0 85.5  
Bowel bother 89.74 83.1 87.0 84.96 88.8 96.4 82.9 92 89.74  95.8    86.3 78.1  
Sexual function 10.02 38.5  17.89 32.5 21.7 25.6 15 10.02 45.2 38.9 21.47 38 25.73 7.3 32.1 26 
Sexual bother 49.15 36.3  53.32 74.2 32.7 40.8 66 49.15 50.7 72.9 33.68  50.92 58.4 47.2 34 
UCLA-PCI: University of California Prostate Cancer Index 
 
Table 5. Results of t-tests comparing current study with other studies 
 
This 
study 
Gacci, et al. 
(22) 
Jayadevappa 
et al. (24) 
Arredondo 
et al. (25) 
Namiki, et 
al., 2006 
Shikanov 
et al. (27) 
Wakatsuki 
et al. (28) 
Inoue, et 
al. (32) 
This 
study 
Litwin, et 
al. (14) 
Krahn, et 
al. (30) 
Wootten, et al. 
(31) 
Korfage, et al. 
(21) 
Berge, et al. 
(33) 
Karakiewicz, 
et al. (29) 
Country Gaza Italy USA USA Japan USA Japan Japan Gaza USA Canada Australia Netherlands Norway Canada 
 X X t-test X t-test X t-test X t-test X t-test X t-test X t-test X X t-test X t-test X t-test X t-test X t-test X t-test 
Physical function 45.09 86.87 14.97 67.7 3.36 80.2 12.31         45.09 72.5 9.2         80.95 12.85 
Role limitation – physical 35.26 72.73 11.03 87.8 11.43 67.6 9.27         35.26 61.3 7.09         70.67 10.77 
Role limitation – emotional 33.97 55.30 6.59 88.9 11.99 80.2 13.81         33.97 71.2 10.43         77.52 13.58 
Vitality 46.84 81.94 14.5 70.6 8.51 62.3 6.40         46.84 62.2 6.14         64.75 7.65 
Mental health 55.56 72.63 8.09 78.9 10.11 77.2 11.28         55.56 76.7 10.68           
Social functioning 59.66 80.18 7.74 92.6 10.36 81.9 7.35         59.66 80.0 6.57         82.13 7.64 
 
 
 
Bodily pain 68.23  86.79   6.44    89.7 6.72 79.5 3.84 68.23  73.3   1.67 81.56 4.64 
General health 59.19  66.36   2.11    74.1 2.65 71.1 3.69 59.19  67.0   2.33 71.31 3.78 
Health transition 50.34  80.05  11.36 50.4 0.02 50.34 
Urinary function 57.08  75.18   5.62    92.4 7.63 69.9 4.18 81 7.55   72.0   4.97   82.5   7.73   71.8   4.21   57.08  83.8   8.68    90 10.99 79.44 6.37 85.0 8.87 79.7 6.84 70.86 4.64 
Urinary bother 39.74  75.44   9.70    89.9    13.24    73.4 9.51 81    11.33  79.0  10.75  79.2   9.72   80.6  10.46  39.74  79.4  23.03 86.89 12.62 80.5 10.87 83.8 15.58 74.30 10.02 
Bowel function 84.96  89.80  2.83    92.9    4.87 84.1 0.52    89 1.44 90.3  2.95    86.0  0.53    84.96  84.4  0.334   88 1.55 86.6 0.91 85.5 0.22 
Bowel bother 89.74  84.96  2.2 94.6    2.31 82.9 3.28    92 1.08 95.8  2.66    86.3  1.38    89.74  83.1  3.06 87.0 1.45 78.1 3.02 
Sexual function 49.15  17.89  11.10  42.1    2.06 25.6 8.57    15 12.13  45.2  1.36    38.9  3.29    7.3    15.43  49.15  38.5  3.68 38 3.83 25.73 7.15 32.1 4.24 21.47 10.54 
Sexual bother 10.02  53.32  23.41  46.4    9,04 40.8 14.68  66 21.45  50.7  15.26  72.9  25.22  58.4  8.21    10.02  36.3  10.42 50.92 11.45 47.2 8.35 33.68 11.86 
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With the high incidence of prostate cancer, 
high survival rates, and with the several poten- 
tial morbidities associated with the different 
treatment methods, more focus on QOL issues 
was observed in the relevant literature (22, 32, 
33, 40). Secchi and Strepparava (41) added that 
QOL is now considered one of the most im- 
portant parameters in evaluating clinical trials. 
Furthermore, the American Cancer Society (6) 
added that managing the consequences of cancer 
itself and treatment-related consequences be- 
come more important because patients live long- 
er with the burdens of treatment consequences. 
Not understanding or not considering these is- 
sues can contribute to poorer recovery, higher 
level of stress, and disturbances in their QOL 
(42). Therefore, this group of patients deserves 
more attention from health policy decision-
makers to improve the quality of their lives and 
improve the quality of provided health care 
services which might be reflected on their QOL. 
The researchers would recommend physicians 
discus with their patients the pros and cons of 
different treatment modalities and to set a plan 
to introduce a prostate cancer screening policy 
into the health care system. 
One of the major limitations to this study was 
that the researchers could not find any study that 
were conducted in a developing country, includ- 
ing  Palestine, to  evaluate QOL  of  men  diag- 
nosed with prostate cancer. In spite this study 
was conducted in a developing country the re- 
sults cannot be generalized to patients diagnosed 
with prostate cancer who live in other develop- 
ing countries. Therefore, the researchers would 
recommend that further research to be conducted 
in other developing countries to measure QOL 
of prostate cancer survivors, preferably using a 
longitudinal design. 
An issue of concern that might affect the re- 
sults of this study is that Gaza Strip had been un- 
der siege since 2006. The siege could affect the 
QOL of people living in Gaza Strip in all aspects 
of their lives. Therefore, these low scores of QOL 
could be due to the impact of the siege. The re- 
searchers would highly recommend conducting a 
comparative study to compare QOL of prostate 
cancer survivors living in Gaza Strip and those 
who live  on  the  other part of  Palestine, West 
Bank, to examine if these results could be at- 
tributed to the impact of the siege or not. 
 
Conclusion 
 
Prostate cancer is one of the most common 
types of cancer. It is also one of the largest caus- 
es of cancer-related deaths among males in the 
world. Survival rates can however be very high; 
especially if the cancer is discovered in its early 
stages. Therefore, it is important to pay more 
attention to the QOL of survivors. Many studies 
have assessed the QOL of prostate cancer survi- 
vors. All these studies were conducted in devel- 
oped countries yet none were found to be con- 
ducted in a developing country and none was 
conducted in Palestine. This study assesses the 
QOL of prostate cancer survivors in a develop- 
ing country (Gaza Strip, Palestine). The results 
revealed that  men  residing in  Gaza Strip had 
lower levels of a QOL than those living in de- 
veloped countries. This difference can be related 
to the availability of advanced medical technol- 
ogy and the screening measures used in the early 
detection of prostate cancer. Diagnosing prostate 
cancer in its early stages will result in improved 
prognosis and survival rates as both  can lead to 
improved QOL. 
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